Managing the side-effects of vasopressin V2 receptor blockade in ADPKD
(1) Lecture (30 minutes and 10 minutes Q&A): Review renal physiology of water clearance and how reduced vasopressin (AVP) V2 receptor (V2R) signaling can lead to polyuria and altered renal hemodynamics. Discuss how this knowledge can be applied for proper interpretation of kidney function changes and optimal management (i.e. polyuria and blood pressure control) of patients with pharmacologic AVP V2R blockage. Potential renal hemodynamic interaction of AVP V2R antagonist, ACEi/ARB, and SGLT2 inhibitor will also be reviewed.
(2) Interactive Case Presentation (45 minutes): Two to three cases (to be provided by Drs. Bichet and Pei) will be presented with polling quizzes for the audience and comments by Drs. Bichet and Pei.
Register Today!
Speakers:
York Pei MD, FRCP(C), FACPProfessor of Medicine, University of Toronto
Nephrologist, Toronto General Hospital, University Health Network
Toronto, ON
Dr. Pei is a Professor of Medicine at the University of Toronto. He is also a staff nephrologist at the Toronto General Hospital, University Health Network, where he directs the Center for Innovative Management for Polycystic Kidney Disease (https://www.cimpkd.ca/our-team.html). He received research training in both Clinical Epidemiology and Human Molecular Genetics. His research program focuses on genetic, genomic, and translational research of hereditary kidney diseases with a major focus on autosomal dominant polycystic kidney disease and is supported by grants from the Kidney Foundation of Canada, Physicians Incorporated Foundation, Polycystic Kidney Disease Foundation (USA), and Canadian Institutes of Health Research. He has published more than 150 peer-reviewed papers and had had served in the Editorial Board for the Journal of American Society of Nephrology and Grant Review Panels for the Kidney Foundation of Canada, Canadian Institutes of Health Research, PKD foundation (USA), and National Institutes of Health, USA. He was a co-recipient of the 2019 Lillian J. Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease (https://www.theisn.org/about-isn/awards-a-prizes/lillian-jean-kaplan-international-prize).
Daniel Bichet MD, FRCP(C), FACPNephrologist, Hôpital du Sacré-Cœur de Montréal
Montréal, QC
Daniel G. Bichet, MD is Professor of Medicine, Pharmacology and Physiology at the Université de Montréal and a staff nephrologist at the Hôpital du Sacré-Coeur de Montréal. He obtained his medical degree at the Université de Besançon (France) and completed additional clinical training at the Hôtel-Dieu de Montréal Hospital (Université de Montréal), Montréal General Hospital, and Royal Victoria Hospital (McGill University). He did a research fellowship at the University of Colorado Health Sciences Center under the mentorship of Dr. Robert Schrier with the encouragements of Dr Julien Marc-Aurèle in Montreal. Dr. Bichet obtained a Canadian Institutes Health Research Chair in Genetics of Renal Diseases from 2003 to 2010. He received the Jonathan Ballon Award of the Quebec Heart and Stroke Foundation, was a scholar of the Heart and Stroke Foundation of Canada and le Fonds de la recherche en santé du Québec (FRSQ). He was also a recipient of a Career Investigator Award of the FRSQ.
Dr. Bichet’s research includes fundamental life-sustaining homeostatic networks for water and osmotic pressure balance in human physiology. His laboratory is contributing to the prevention of extreme dehydration states in children with polyuric disorders (Nephrogenic Diabetes Insipidus). Dr. Bichet received the Medal of the Kidney Foundation of Canada in 1998, a Doctorat Honoris Causa from the University of Nancy (France) in 1999, and the Jean Hamburger Medal (the highest distinction of the European Society of Nephrology) in 2010. Bichet D.G. Regulation of thirst and vasopressin release, Annual Review of Physiology, Feb 10;81:359 373. 2019. Bichet DG. GENETICS IN ENDOCRINOLOGY Pathophysiology, diagnosis and treatment of familial nephrogenic diabetes insipidus. Eur J Endocrinol. 2020 Aug;183(2):R29-R40. doi: 10.1530/EJE-20-0114.PMID: 32580146 Review.